Comparative Pharmacology
Head-to-head clinical analysis: MONJUVI versus TECENTRIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONJUVI versus TECENTRIQ.
MONJUVI vs TECENTRIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MONJUVI (tafasitamab-cxix) is a humanized Fc-engineered CD19-directed cytolytic monoclonal antibody. It binds to CD19 antigen on the surface of pre-B and mature B lymphocytes, and upon binding, facilitates antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
Atezolizumab is a humanized monoclonal IgG1 antibody that binds to PD-L1, blocking its interaction with PD-1 and CD80 receptors, thereby reversing PD-L1-mediated inhibition of T-cell activation and restoring anti-tumor immune responses.
3 mg/kg intravenously over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
800 mg intravenously every 2 weeks; or 1200 mg intravenously every 3 weeks; or 1680 mg intravenously every 4 weeks.
None Documented
None Documented
Terminal half-life: approximately 17 days (range 11-27 days). This supports a dosing interval of every 2 weeks, as steady state is reached by approximately 70 days.
Terminal elimination half-life is approximately 27 days (range: 20–35 days). This long half-life supports every-3-week dosing and reflects slow clearance typical of IgG1 antibodies.
Monjuvi (tafasitamab-cxix) is a monoclonal antibody primarily catabolized into small peptides and amino acids. No specific data on renal or biliary excretion; minimal intact drug excreted in urine or feces. Expected to undergo general protein degradation.
Tecentriq (atezolizumab) is a monoclonal antibody; elimination occurs via intracellular catabolism into amino acids. No renal or biliary/fecal excretion of intact drug. 0% unchanged in urine or feces.
Category C
Category C
Antineoplastic
Antineoplastic, PD-L1 Inhibitor